Sartorius opens German production facility for bioreactors

Friday, September 14, 2012 12:19 PM

Sartorius, the Germany-based international laboratory and process technology provider, has officially opened its new plant in Guxhagen, Germany, for the manufacture of bioreactors.

After approximately one year of construction and $23.5 million, the new building will now manufacture bioreactors and further production equipment for customers in the biopharmaceutical industry. Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for 240 employees. The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment,” said Joachim Kreuzburg, CEO and executive board chairman, Sartorius. “As a result, we are optimally prepared for further expansion, especially for single-use bioreactors.”

Sartorius has moved all operations from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs